Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Precision NanoSystems Named as One of British Columbia’s Fastest Growing Companies

Precision NanoSystems
Posted on: 20 Dec 17

Precision NanoSystems is one of the fastest growing businesses in British Columbia (BC) according to the recently published Top 100 fastest-growing companies in BC list from business news journalBusiness in Vancouver (BIV). This annual list looks at several factors indicating company growth over the last five years – from changing company revenues to number of employees – and ranks Precision NanoSystems in third place, up from 10th place in last year’s list.

Precision NanoSystems’ revenues have grown from $81,133 (CAD) in 2012 to over $3m in 2016, an increase in excess of 3,750 percent. This strong financial performance has been underpinned by the company’s NanoAssemblr™ technology platform, which enables rapid nanoparticle formulation and seamless scale-up for clinical development. “Our company’s focus is on accelerating the creation of transformative medicine that significantly impacts human well-being,” said Dr James Taylor, CEO and co-founder.

“We have achieved some major milestones over the past year, and are pleased to be recognized by BIV. We have over 50 employees worldwide, with 170 systems deployed across more than 20 countries. Over 60 companies are now using the NanoAssemblr platform™, including 10 of the top 15 pharmaceutical manufacturers, resulting in more than 250,000 runs completed. The strong growth of both our company and customer-base highlights the potential of the NanoAssemblr platform™, and our ongoing commitment to transform nanomedicine technologies.”

To learn more about Precision NanoSystems, visit

About Precision NanoSystems, Inc.

Precision NanoSystems Inc. (PNI) creates innovative solutions for the discovery, development and manufacture of novel nanoparticles for use as medicines and in medical research. PNI’s proprietary NanoAssemblr Platform™ enables the rapid, reproducible, and scalable manufacture of next generation nanoparticle formulations for the targeted delivery of therapeutic and diagnostic agents to cells and tissues in the body. PNI provides instruments, reagents and services to life sciences researchers, including pharmaceutical companies, and builds strategic collaborations to revolutionize healthcare through nanotechnology. For more information, visit

© 2017 kdm communications limited

View source version on

Business Wire

Last updated on: 20/12/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.